Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 1999 June;11(2) > Minerva Biotecnologica 1999 June;11(2):107-12

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

  FLOW CYTOMETRY IN IMMUNOLOGY AND HEMATOLOGYFREEfree


Minerva Biotecnologica 1999 June;11(2):107-12

Copyright © 1999 EDIZIONI MINERVA MEDICA

lingua: Inglese

Circulating hematopoietic progenitor cells. Biological aspects and clinical applications

Danova M., Porta C., Ferrari S.

Internal Medicine and Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy


FULL TEXT  


Hematopoietic pro­gen­i­tor ­cells set up a ­very het­er­o­ge­ne­ous cel­lu­lar com­part­ment, com­pris­ing ­many dif­fer­ent stag­es of dif­fe­ren­ti­a­tion ­from extreme­ly prim­i­tive ele­ments to ­more ­mature ­cells com­mit­ted to dif­fe­ren­ti­a­tion. Early hemat­o­poiet­ic ­cells are iden­ti­fied by a mono­clo­nal anti­body bind­ing a ­cell-sur­face mole­cule, des­ig­nat­ed as CD34+. These ­cells can be mobi­lized ­into the periph­er­al ­blood by cyto­tox­ic ­drugs, cyto­kines or the com­bi­na­tion of ­both, allow­ing ­their col­lec­tion by apher­e­sis and ­used to facil­i­tate hemat­o­poiet­ic recov­ery ­after myel­oa­bla­tive chem­o­ther­a­py for ­patients ­with can­cer. These ­cells can be sub­set and quan­ti­fied by ­flow cytom­e­try; ­this tech­nique is ­also use­ful to deter­mine in a clin­i­cal set­ting the appro­pri­ate tim­ing for the apher­e­sis, as ­well as to mon­i­tor the CD34+ ­cell ­yield with­in the aph­e­ret­ic prod­uct. To ­date, the auto­tran­splan­ta­tion of periph­er­al ­blood-­derived pro­gen­i­tor ­cells is play­ing an impor­tant ­role in the med­i­cal treat­ment of leu­ke­mi­as, lym­pho­mas and ­some sol­id ­tumors. In ­this set­ting, an advan­tage of pro­gen­i­tor ­cells mobi­lized ­into the ­blood ­over ­their ­bone mar­row coun­ter­part is the ­increased ­speed of hemat­o­poiet­ic recon­sti­tu­tion ­after myel­oa­bla­tive ther­a­py. The ­future use of CPCs is relat­ed to the devel­op­ment of ex ­vivo expan­sion strat­e­gies ­aimed at increas­ing ­their num­ber as ­well as to pro­duce ­large num­bers of a par­tic­u­lar ­cell ­type for a pre­cise appli­ca­tion ­such as use as a vehi­cle for ­gene ther­a­py.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail